VIVUS Third Quarter 2009 Results  Today's Calls

· Shareholder.com · Shareholder.com Webcasting Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 3 Calls Today's Calls

Call Details VIVUS Third Quarter 2009 Results Tue, Nov 3, 2009, 4:30 pm Eastern Listen to the archived event audio About VIVUS, Inc. (NasdaqGM:VVUS) VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. The company offers MUSE, a minimally invasive therapy for erectile dysfunction. It develops drug candidates that address the need of obesity, diabetes, and sexual health markets. The company’s late-stage clinical products, which are under development, include Qnexa that is in phase 3 clinical trials for obesity and completed phase 2 clinical trials for diabetes; Avanafil, which is in phase 3 studies to treat erectile dysfunction; and Luramist, for which the phase 2 study is completed for the treatment of hypoactive sexual desire disorder in women. It has a development, licensing, and supply agreement with Tanabe Seiyaku Co., Ltd. for the development of Avanafil; and licensing agreements with Acrux and its subsidiary to develop and, if approved, commercialize Luramist and Evamist in the United States. The company was founded in 1991 and is headquartered in Mountain View, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings